Evidence map›Paper›PMID 20375137›Full record

ArticleBrain : a journal of neurology2010

Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2.

Suman Jayadev, James B Leverenz, Ellen Steinbart, Justin Stahl, William Klunk, Cheng-En Yu, Thomas D Bird

Open access · bronzeAbstract readCase ReportsComparative Study
In one paragraph

Article in Brain : a journal of neurology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 124 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
124citing papers in PubMed, 2 pooled it
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

124 citing papers in PubMed, 2 syntheses or guidelines pooled it, 259 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Presence of Alzheimer's disease variants in circular RNA ofJournal of Alzheimer's disease : JAD · 2025
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. The curious case of a heterozygous loss-of-functionMolecular neurodegeneration advances · 2025
    Article
  16. Article
  17. Identifying Alzheimer's disease-associated genes using PhenoGeneRanker.bioRxiv : the preprint server for biology · 2024
    Article
  18. Review
  19. Review
  20. Article

64 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Suman JayadevDepartment of Neurology, University of Washington, 1660 S Columbian Way, 182-GRECC, Seattle, WA 98108, USA.
James B Leverenz
Ellen Steinbart
Justin Stahl
William Klunk
Cheng-En Yu
Thomas D Bird
University of Washington · USGeriatric Research Education and Clinical Center · USUniversity of Pittsburgh · USVA Puget Sound Health Care System · US

Funding

THERAPEUTIC EFFECTS OF INTRA-NASAL INSULIN DETEMIRP50AG005136 · NIA · UNIVERSITY OF WASHINGTON · PI JAYADEY, SUMAN · 1985 to 2019
$57.2M
Vascular Moderators of the Impact of Alzheimer's Pathology in the Young-OldP01AG025204 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Milos D Ikonomovic · 2005 to 2026
$56.5M
TREATMENT OF DEPRESSION IN ALZHEIMER'S DISEASEP50AG005133 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BECKER, JAMES T. · 1985 to 2019
$43.0M
Roles of Gray Matter Brain Aging and Small Vessel Disease in AD PathophysiologyRF1AG025516 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI AIZENSTEIN, HOWARD J, VILLEMAGNE, VICTOR LUIS · 2014 to 2021
$9.0M
AMYLOID PATHOLOGY AND COGNITION IN NORMAL ELDERLYR37AG025516 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KLUNK, WILLIAM E · 2005 to 2014
$4.3M
NIA NIH HHS P01 AG025204NIA NIH HHS P50 AG005133NIA NIH HHS P50 AG005136NIA NIH HHS R37 AG025516NIA NIH HHS RF1 AG025516
6 · The paper itself

Abstract

Mutations in presenilin 2 are rare causes of early onset familial Alzheimer's disease. Eighteen presenilin 2 mutations have been reported, although not all have been confirmed pathogenic. Much remains to be learned about the range of phenotypes associated with these mutations. We have analysed our unique collection of 146 affected cases in 11 Volga German families, 101 who are likely to have the same N141I mutation in presenilin 2 (54 genotyped confirmed). We have also assessed the detailed neuropathologic findings in 18 autopsies from these families and reviewed the world's literature on other presenilin 2 mutations; presenting a novel mutation that is predicted to lead to a premature truncation codon. Seven presenilin 2 mutations reported in the literature have strong evidence for pathogenicity whereas others may be benign polymorphisms. One hundred and one affected persons, with sufficient historical information from the Volga German pedigrees (N141I mutation), had a mean onset age of 53.7 years+/-7.8 (range 39-75) and mean age at death of 64.2 years+/-9.8 (range 43-88). These figures overlap with and generally fall between the results from the subjects in our centre who have late onset familial Alzheimer's disease or mutations in presenilin 1. Seizures were noted in 20 (30%) of 64 subjects with detailed medical records. Two mutation carriers lived beyond age 80 without developing dementia, representing uncommon examples of decreased penetrance. Two persons had severe amyloid angiopathy and haemorrhagic stroke. Eighteen cases had detailed histopathology available and analysed at our institution. Braak stage was five or six, amyloid angiopathy and neuritic plaques were common and more than 75% had Lewy bodies in the amygdala. TAR DNA-binding protein-43 inclusions were uncommon. In addition, a 58-year-old female with a 2 year course of cognitive decline and no family history of dementia has abnormal fludeoxyglucose-positron emission tomography imaging and a novel 2 base pair deletion in presenilin 2 at nucleotide 342/343, predicted to produce a frame-shift and premature termination. We conclude that mutations in presenilin 2 are rare with only seven being well documented in the literature. The best studied N141I mutation produces an Alzheimer's disease phenotype with a wide range of onset ages overlapping both early and late onset Alzheimer's disease, often associated with seizures, high penetrance and typical Alzheimer's disease neuropathology. A novel premature termination mutation supports loss of function or haploinsufficiency as pathogenic mechanisms in presenilin 2 associated Alzheimer's disease.

Indexed as

PhenotypeAdultAgedAged, 80 and overAlzheimer DiseaseAmino Acid SequenceAsparagineFemaleGenetic Carrier ScreeningGenotypeHumansIsoleucineMaleMiddle AgedMolecular Sequence DataMutationAsparagineIsoleucinePresenilin-2

Identifiers

PMID20375137
PMCPMC2850581
OpenAlexW2055776806

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.